Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2011 Jul;86(7):625-7.
doi: 10.1002/ajh.22041.

Comparison of autologous stem cell transplantation versus consolidation chemotherapy for patients with cytogenetically normal acute myeloid leukemia (CN-AML) and FLT3ITD

Harshabad Singh  1 , Lillian L Werner, Salma Asali, Daniel J DeAngelo, Karen K Ballen, Philip C Amrein, Martha Wadleigh, Ilene Galinsky, Brian Wolpin, Joseph Pidala, Donna S Neuberg, Edward A Fox, Richard M Stone, Eyal C Attar
Affiliations
Comparative Study

Comparison of autologous stem cell transplantation versus consolidation chemotherapy for patients with cytogenetically normal acute myeloid leukemia (CN-AML) and FLT3ITD

Harshabad Singh et al. Am J Hematol. 2011 Jul.

Abstract

We retrospectively analyzed clinical outcomes of patients aged 18–59 with cytogenetically normal AML (CN-AML) and mutations in the FLT3 receptor according to type of postremission therapy. Specifically, we compared the outcomes of patients who underwent autologous SCT versus consolidation chemotherapy. There were 37 patients with an ITD mutation (7 also had a TKD mutation) and 19 patients with an isolated TKD mutation at diagnosis. In all, patients with an isolated TKD (n=16) had an improved DFS and OS (p=.031 and .014, respectively) compared to ITD patients (n=21). For individuals with an isolated TKD mutation, survival outcomes were similar irrespective of the type of postremission therapy (n=7 for SCT and 9 for chemotherapy) (p=0.97 and 0.082, respectively). However, ITD positive patients who underwent an SCT in CR1 (n=10) had an improved DFS but similar OS compared to those who received consolidation chemotherapy (n=11) (p=.05 and .27). These results suggest that high dose chemotherapy with autologous SCT may be a reasonable therapeutic choice over consolidation chemotherapy for young CN-AML patients with a FLT3ITD mutation.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest

Dr. Richard M Stone has served as a consultant for Novartis

Figures

Figure 1
Figure 1
A. DFS in months of patients with FLT3R ITD according to type of postremission therapy initiated B. OS in months of patients with FLT3R ITD according to type of postremission therapy initiated
See this image and copyright information in PMC

References

    1. Zander AR, Bacher U, Finke J. Allogeneic stem cell transplantation in acute myeloid leukemia: establishment of indications on the basis of individual risk stratification. Dtsch Arztebl Int. 2008;105:663–669. - PMC - PubMed
    1. Estey E, Dohner H. Acute myeloid leukaemia. Lancet. 2006;368:1894–1907. - PubMed
    1. Slovak ML, Kopecky KJ, Cassileth PA, Harrington DH, Theil KS, Mohamed A, Paietta E, Willman CL, Head DR, Rowe JM, Forman SJ, Appelbaum FR. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood. 2000;96:4075–4083. - PubMed
    1. Byrd JC, Mrozek K, Dodge RK, Carroll AJ, Edwards CG, Arthur DC, Pettenati MJ, Patil SR, Rao KW, Watson MS, Koduru PR, Moore JO, Stone RM, Mayer RJ, Feldman EJ, Davey FR, Schiffer CA, Larson RA, Bloomfield CD. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461) Blood. 2002;100:4325–4336. - PubMed
    1. Gregory TK, Wald D, Chen Y, Vermaat JM, Xiong Y, Tse W. Molecular prognostic markers for adult acute myeloid leukemia with normal cytogenetics. J Hematol Oncol. 2009;2:23. - PMC - PubMed

Publication types

Substances